Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer

Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 225(2021) vom: 01. Apr., Seite 108679
1. Verfasser: Chick, R Connor (VerfasserIn)
Weitere Verfasser: Clifton, G Travis, Hale, Diane F, Vreeland, Timothy J, Hickerson, Annelies T, Kemp Bohan, Phillip M, McCarthy, Patrick M, Litton, Jennifer K, Alatrash, Gheath, Murthy, Rashmi K, Qiao, Na, Philips, Anne, Lukas, Jason, Holmes, Jarrod P, Mittendorf, Elizabeth A, Peoples, George E
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Breast cancer Cancer vaccine Immunotherapy Personalized medicine Cancer Vaccines mehr... HER2 peptide (369-377) HLA-A24 Antigen Peptide Fragments Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1 ERBB2 protein, human EC 2.7.10.1 Receptor, ErbB-2 Trastuzumab P188ANX8CK
Online verfügbar Volltext